参考文献

[1] 曹广文.以社区为基础的群体医学在恶性肿瘤预防和控制中的重要意义.第二军医大学学报,2014,35(1):1-7.

[2] Jemal A,Bray F,Center MM,et al.Global cancer statistics.CA Cancer J Clin,2011,61(2):69-90.

[3] El-Serag HB.Hepatocellular carcinoma.N Engl J Med,2011,365(12):1118-1127.

[4] Mazzaferro V,Regalia E,Doci R,et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med,1996,334(11):693-699.

[5] 韩雪,黄辰曦,张宏伟,等.2002-2010 年上海市杨浦区居民原发性肝癌发病及生存情况.中华预防医学杂志,2012,46(2):119-124.

[6] Cao G.Exploring risk factors of hepatitis B virus-associated hepatocellular carcinoma: prospective verse retrospective studies.J Gastroenterol,2011,46(1):125-127.

[7] Chang MH,You SL,Chen CJ,et al.Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees:a 20-year follow-up study.J Natl Cancer Inst,2009,101(19):1348-1355.

[8] Yin J,Zhang H,He Y,et al.Distribution and hepatocellular carcinoma-related viral properties of hepatitis B virus genotypes in Mainland China:a community-based study.Cancer Epidemiol Biomarkers Prev,2010,19(3):777-786.

[9] Caldwell SH,Oelsner DH,Iezzoni JC,et al.Cryptogenic cirrhosis:clinical characterization and risk factors for underlying disease.Hepatology,1999,29(3):664-669.

[10] Moore MA,Park CB,Tsuda H.Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts.Eur J Cancer Prev,1998,7(2):89-107.

[11] Kay A,Zoulim F.Hepatitis B virus genetic variability and evolution.Virus Res,2007,127(2):164-176.

[12] Liu S,Zhang H,Gu C,et al.Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma:a meta-analysis.J Natl Cancer Inst,2009,101(15):1066-1082.

[13] Xie JX,Zhao J,Yin JH,et al.Association of novel mutations and haplotypes in the preS region of hepatitis B virus with hepatocellular carcinoma.Front Med China,2010,4(4):419-429.

[14] Yin J,Xie J,Liu S,et al.Association between the various mutations in viral core promoter region to different stages of hepatitis B,ranging of asymptomatic carrier state to hepatocellular carcinoma.Am J Gastroenterol,2011,106(1):81-92.

[15] Schaefer S.Hepatitis B virus taxonomy and hepatitis B virus genotypes.World J Gastroenterol,2007,13(1):14-21.

[16] Chan HL,Hui AY,Wong ML,et al.Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.Gut,2004,53(10):1494-1498.

[17] Zhang Q,Cao G.Genotypes,mutations,and viral load of hepatitis B virus and the risk of hepatocellular carcinoma:HBV properties and hepatocarcinogenesis.Hepat Mon,2011,11(2):86-91.

[18] Cao GW.Clinical relevance and public health significance of hepatitis B virus genomic variations.World J Gastroenterol,2009,15(46):5761-5769.

[19] Yin JH,Zhao J,Zhang HW,et al.HBV genotype C is independently associated with cirrhosis in community-based population.World J Gastroenterol,2010,16(3):379-383.

[20] Huang YT,Jen CL,Yang HI,et al.Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C.J Clin Oncol,2011,29(27):3643-3650.

[21] Yin J,Zhang H,Li C,et al.Role of hepatitis B virus genotype mixture,subgenotypes C2 and B2 on hepatocellular carcinoma:compared with chronic hepatitis B and asymptomatic carrier state in the same area.Carcinogenesis,2008,29(9):1685-1691.

[22] Zhang HW,Yin JH,Li YT,et al.Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai,China.Gut,2008,57(12):1713-1720.

[23] Kwon H,Lok AS.Hepatitis B therapy.Nat Rev Gastroenterol Hepatol,2011,8(5):275-284.

[24] Tong MJ,Blatt LM,Kao JH,et al.Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma:a comparison with chronic carriers.Liver Int,2007,27(10):1356-1363.

[25] Yuan J,Zhou B,Tanaka Y,et al.Hepatitis B virus(HBV)genotypes/subgenotypes in China:mutations in core promoter and precore/core and their clinical implications.J Clin Virol,2007,39(2):87-93.

[26] Han YF,Zhao J,Ma LY,et al.Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma.World J Gastroenterol,2011,17(38):4258-4270.

[27] Jang JW,Lee YC,Kim MS,et al.A 13-year longitudinal study of the impact of double mutations in the core promoter region of hepatitis B virus on HBeAg seroconversion and disease progression in patients with genotype C chronic active hepatitis.J Viral Hepat,2007,14(3):169-175.

[28] Ferns RB,Naoumov NV,Gilson RJ,et al.Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss.J Clin Virol,2007,39(3):199-204.

[29] Chen CH,Hung CH,Lee CM,et al.Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients.Gastroenterology,2007,133(5):1466-1474.

[30] Kuang SY,Jackson PE,Wang JB,et al.Specific mutations of hepatitis B virus in plasma predict liver cancer development.Proc Natl Acad Sci U S A,2004,101(10):3575-3580.

[31] Zhang H,Zhai Y,Hu Z,et al.Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers.Nat Genet,2010,42(9):755-758.

[32] Chan KY,Wong CM,Kwan JS,et al.Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection.PLoS One,2011,6(12):E28798.

[33] Miki D,Ochi H,Hayes CN,et al.Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers.Nat Genet,2011,43(8):797-800.

[34] Kumar V,Kato N,Urabe Y,et al.Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma.Nat Genet,2011,43(5):455-458.

[35] Zhang Q,Pu R,Du Y,et al.Non-coding RNAs in hepatitis B or C-associated hepatocellular carcinoma:potential diagnostic and prognostic markers and therapeutic targets.Cancer Lett,2012,321(1):1-12.

[36] Xu T,Zhu Y,Wei QK,et al.A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma.Carcinogenesis,2008,29(11):2126-2131.

[37] Razumilava N, Gores GJ.Cholangiocarcinoma.Lancet,2014,9935(383):2168-2179.

[38] Mclean L,Patel T.Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States.Liver Int,2006,26(9):1047-1053.

[39] Blechacz BR,Gores GJ.Cholangiocarcinoma.Clin Liver Dis,2008,12(1):131-150.

[40] Hsing AW,Gao YT,Devesa SS,et al.Rising incidence of biliary tract cancers in Shanghai,China.Int J Cancer,1998,75(3):368-370.

[41] 吴志勇,罗蒙.肝内胆管癌的新认识.外科理论与实践,2009,14(2):135-139.

[42] 梁力建,邓伟.肝胆管结石和肝胆管癌.临床外科杂志,2005,13(7):409-410.

[43] Terada T,Ashida K,Endo K,et al.c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma.Histopathology,1998,33(4):325-331.

[44] 吴胜东,陆才德.肝内胆管癌诊治进展.现代实用医学,2004,16(9):561-563.

[45] Fu XH,Tang ZH,Zong M,et al.Clinicopathologic features, diagnosis and surgical treatment of intrahepatic cholangiocarcinoma in 104 patients.Hepatobiliary Pancreat Dis Int,2004,3(2):279-283.

[46] Ohshio G,Manabe T,Watanabe Y,et al.Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases:evaluation of the influence of obstructive jaundice.Am J Gastroenterol,1990,85(10):1370-1376.

[47] Deng Y,Du Y,Zhang Q,et al.Human cytidine deaminases facilitate hepatitis B virus evolution and link inflammation and hepatocellular carcinoma.Cancer Lett,2014,343(2):161-171.

[48] Liu S,Li N,Yu X,et al.Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells.Gastroenterology,2013,144(5):1031-1041.

[49] Gad H,Koolmeister T,Jemth AS,et al.MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.Nature,2014,7495(508):215-221.

[50] Huber KV,Salah E,Radic B,et al.Stereospecific targeting of MTH1 by(S)-crizotinib as an anticancer strategy.Nature,2014,7495(508):222-227.